E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer
In this solo episode of AI For Pharma Growth, Dr Andree Bates explains why “we’re doing AI” is not a credible board answer, and why activity, pilots and steering committees are not the same as strategy.
Dr Andree breaks down two common answers leadership teams give when asked about AI strategy.
The episode explores why crowdsourced use cases often become “use case copying” rather than genuine internal innovation. A pain point may be real, and a pilot may work, but that does not mean it is one of the highest-value AI opportunities for the organisation. Without financial modelling, business-unit submissions are only inputs, not prioritisation.
Dr Andree also outlines four structural conditions that explain why AI investment often fails to realise value: the value prioritisation gap, the decision rights gap, the data ownership conflict, and incentive misalignment. These issues are connected, and if they are diagnosed in the wrong order, the strategy usually fails at the next layer.
The core message is clear: boards do not need a list of AI activity. They need a strategy they can govern, with clear priorities, financial assumptions, sequencing, ownership and metrics that can be tested over time.
Topics Covered
Why “we’re doing AI” is not a board answer
Activity, demand and value: the difference that matters
Why business-unit use cases are not strategy
Use case copying and internal innovation theatre
The value prioritisation gap
Decision rights between pilot and production
Data ownership and access conflicts
Incentives, adoption and rational resistance
What finance needs to see before funding AI
What a real board-level AI answer sounds like
Eularis helps pharma and biotech leaders turn AI activity into board-defensible governed strategy and measurable commercial outcomes.
If your CFO asked tomorrow for the projected return of each major AI initiative - by year, across three years, with explicit adoption, operating cost and redeployment assumptions - could you produce an answer that survives scrutiny?
And if you could: would you know which of those initiatives most moves the company toward the outcomes it's exposed on over the next three years? Those are two different questions, and most organisations can't answer either. A strong initiative-level ROI tells you a project is defensible. It doesn't tell you it belongs among your top five. Capital spent on a second-order opportunity is capital no longer available for a first-order one — and no amount of downstream rigour recovers value that was never strategically prioritised.
The Eularis AI Strategic Blueprint models both levels: a financial case for every prioritised initiative, and a rigorously modelled ranking of which ones create the most material value against your commercial objectives — then sequences them by dependency rather than enthusiasm, with governance designed for pharma's regulatory reality. See what a board-defensible AI strategy contains → eularis.com/ai-strategic-blueprint-for-pharma
About the Podcast
AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.